Entering text into the input field will update the search result below
Try for free
Search for Symbols, analysts, keywords

Candel sees top-line phase 2 data on lung cancer candidate in Q2 2024

Jun. 13, 2023 8:37 AM ETCandel Therapeutics, Inc. (CADL)By: Jonathan Block, SA News Editor
Lung Cancer Drawn Concept

IvelinRadkov

  • Candel Therapeutics (NASDAQ:CADL) said it plans to release top-line phase 2 data on non-small cell lung cancer (NSCLC) candidate CAN-2409 in Q2 2024.
  • The overall survival data is on CAN-2409 plus valacyclovir in combination with an immune checkpoint inhibitor in patients with non-resectable, stage III/IV NSCLC who progressed while on a PD-(L)1 inhibitor.
  • Seeking Alpha's Quant Rating views Candel (CADL) as a strong sell.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.